Clearmind Medicine Streamlines Reporting Obligations

TipRanksMay 1 21:19

Clearmind Applies to Cease Being a Reporting Issuer in Canada

Vancouver, Canada, April 30, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWYO) ("Clearmind" or the "Company"), a clinical- stage biotech company focused on discovery and

GlobeNewswireMay 1 04:15

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati

BenzingaApr 17 21:13

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of no

Clearmind MedicineApr 17 12:00

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Vancouver, Canada, April 10, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel

Clearmind MedicineApr 10 12:00

Clearmind Medicine CEO Issues Letter to Shareholders

Vancouver, Canada, April 09, 2024 -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE:CWY0) ("Clearmind" or the "company"), a clinical-stage biotech company focused on discovery and development of novel ps

Clearmind MedicineApr 9 12:00